Stockscreener 앱 받기
8.02
1.91%
0.15
시간 외 거래:
8.27
0.25
+3.12%
전일 마감가:
$7.87
열려 있는:
$7.86
하루 거래량:
23,974
Relative Volume:
0.51
시가총액:
$84.59M
수익:
$2.09M
순이익/손실:
$-5.28M
주가수익비율:
-11.97
EPS:
-0.67
순현금흐름:
$-3.64M
1주 성능:
+2.82%
1개월 성능:
+23.38%
6개월 성능:
+70.28%
1년 성능:
+33.89%
1일 변동 폭
$7.7742
$8.25
1주일 범위
$7.518
$8.41
52주 변동 폭
$3.7223
$11.78
Nutriband Inc Stock (NTRB) Company Profile
명칭
Nutriband Inc
전화
407 377-6695
주소
121 S. ORANGE AVE., ORLANDO
NTRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRB
Nutriband Inc
|
8.02 | 84.59M | 2.09M | -5.28M | -3.64M | -0.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nutriband Inc Stock (NTRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-22 | 개시 | Noble Capital Markets | Outperform |
Nutriband Inc 주식(NTRB)의 최신 뉴스
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-Up for Aversa?? Fentanyl Abuse Deterrent Fentanyl Patch - MarketScreener
Nutriband and Kindeva Complete Commercial Manufacturing - GlobeNewswire
Nutriband and Kindeva Complete Commercial Manufacturing Process - GuruFocus
Nutriband (NTRB) Advances Aversa Fentanyl Manufacturing Process | NTRB Stock News - GuruFocus
Nutriband, Kindeva complete commercial manufacturing process scale-up for Aversa - TipRanks
Revolutionary Abuse-Deterrent Fentanyl Patch Completes Manufacturing Scale-up: $200M Market Potential - Stock Titan
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development - citybuzz -
(NTRB) Proactive Strategies - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology - The Globe and Mail
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology - citybuzz -
Nutriband secures US patent for abuse deterrent patch technology By Investing.com - Investing.com South Africa
Nutriband issued U.S. patent for transdermal abuse deterrent technology - TipRanks
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology - The Manila Times
Nutriband secures US patent for abuse deterrent patch technology - Investing.com Australia
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband (NTRB) Secures Patent for Abuse Deterrent Technology | NTRB Stock News - GuruFocus
Nutriband Secures Game-Changing Patent for First-Ever Abuse-Deterrent Fentanyl Patch Technology - Stock Titan
Nutriband (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology - Barchart.com
Nutriband (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value - The Globe and Mail
Nutriband Inc. Pioneers Abuse-Deterrent Technology with AVERSA, Targets $800 Million Market Potential - citybuzz -
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference - GlobeNewswire
Nutriband (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference - The Globe and Mail
Nutriband CEO Reveals Growth Strategy: Exclusive Virtual Presentation at Noble Capital Conference - Stock Titan
Nutriband reports Q1 revenue up 63% y/y at $667K - TipRanks
Nutriband First Quarter 2026 Earnings: EPS Beats Expectations - Yahoo Finance
Nutriband (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development - The Globe and Mail
Nutriband Inc. Reports Revenue Results for the First Quarter Ended April 30, 2025 - MarketScreener
Nutriband Inc. Provides Update on the Development of AVERSA Fentanyl - MarketScreener
Nutriband (NTRB) Expands Kinesiology Tape Production and Advances Drug Delivery Solutions | NTRB Stock News - GuruFocus
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl - The Manila Times
Nutriband Inc. Quarterly Report Highlights Record Revenue - GlobeNewswire
Nutriband Q1 Revenue Surges 63% as AVERSA Fentanyl Development Advances | NTRBW Stock News - Stock Titan
Nutriband Inc. (NTRB) reports Q1 loss, misses revenue estimates - FXStreet
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates - MSN
NutriBand Inc. SEC 10-Q Report - TradingView
(NTRB) Investment Analysis - news.stocktradersdaily.com
Nutriband Addresses Opioid Pain Management Challenges with Innovative Transdermal Solution - citybuzz -
Nutriband (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode Of The Biomedwire Podcast Featuring Gareth Sheridan, CEO Of Nutriband Inc. - marketscreener.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc. - GlobeNewswire
Nutriband (NASDAQ: NTRB) Charts Path To Commercialization - Barchart.com
Stocks in play: Brookfield Corporation - The Globe and Mail
Nutriband Advances Opioid Pain Patch Technology with Strategic Partnership - citybuzz -
Concern Rises over Market Valutions and Structural Vibrations - The Globe and Mail
(NTRB) On The My Stocks Page - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances - Barchart.com
Nutriband Expands Market Presence Through Strategic Health Industry Partnerships - citybuzz -
Why Isn't Palantir's Stock Taking Off After Another Strong Quarter? - The Globe and Mail
Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch - Barchart.com
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis Regulatory Changes - citybuzz -
Nutriband (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape - Barchart.com
Nutriband Inc (NTRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.42%
자본화:
|
볼륨(24시간):